238 related articles for article (PubMed ID: 31974286)
21. Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial.
Nadkarni GN; Rao V; Ismail-Beigi F; Fonseca VA; Shah SV; Simonson MS; Cantley L; Devarajan P; Parikh CR; Coca SG
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1343-1352. PubMed ID: 27189318
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin.
Ghadrdan E; Ebrahimpour S; Sadighi S; Chaibakhsh S; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Oct; 26(7):1643-1649. PubMed ID: 32046578
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
24. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
25. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients.
Sisman P; Gul OO; Dirican M; Bal AS; Cander S; Erturk E
Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013365
[TBL] [Abstract][Full Text] [Related]
26. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
Kittiskulnam P; Srijaruneruang S; Chulakadabba A; Thokanit NS; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Am J Nephrol; 2020; 51(1):24-34. PubMed ID: 31752000
[TBL] [Abstract][Full Text] [Related]
27. Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease.
Duan S; Chen J; Wu L; Nie G; Sun L; Zhang C; Huang Z; Xing C; Zhang B; Yuan Y
J Diabetes Complications; 2020 Oct; 34(10):107665. PubMed ID: 32653382
[TBL] [Abstract][Full Text] [Related]
28. Assessing urinary levels of IL-18, NGAL and albumin creatinine ratio in patients with diabetic nephropathy.
Sueud T; Hadi NR; Abdulameer R; Jamil DA; Al-Aubaidy HA
Diabetes Metab Syndr; 2019; 13(1):564-568. PubMed ID: 30641767
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
30. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
[TBL] [Abstract][Full Text] [Related]
31. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes.
Lobato GR; Lobato MR; Thomé FS; Veronese FV
Braz J Med Biol Res; 2017 Mar; 50(5):e6106. PubMed ID: 28380198
[TBL] [Abstract][Full Text] [Related]
32. Assessment of kidney function in diabetic patients. Is there a role for new biomarkers NGAL, cystatin C and KIM-1?
Matys U; Bachorzewska-Gajewska H; Malyszko J; Dobrzycki S
Adv Med Sci; 2013; 58(2):353-61. PubMed ID: 24384771
[TBL] [Abstract][Full Text] [Related]
33. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
34. Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease.
Gohda T; Kamei N; Koshida T; Kubota M; Tanaka K; Yamashita Y; Adachi E; Ichikawa S; Murakoshi M; Ueda S; Suzuki Y
J Diabetes Investig; 2020 Mar; 11(2):435-440. PubMed ID: 31483944
[TBL] [Abstract][Full Text] [Related]
35. Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study.
Zeng XF; Lu DX; Li JM; Tan Y; Li Z; Zhou L; Xi ZQ; Zhang SM; Duan W
BMC Nephrol; 2017 Jul; 18(1):233. PubMed ID: 28701152
[TBL] [Abstract][Full Text] [Related]
36. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
Peters HP; Waanders F; Meijer E; van den Brand J; Steenbergen EJ; van Goor H; Wetzels JF
Nephrol Dial Transplant; 2011 Nov; 26(11):3581-8. PubMed ID: 21467131
[TBL] [Abstract][Full Text] [Related]
37. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Nielsen SE; Andersen S; Zdunek D; Hess G; Parving HH; Rossing P
Kidney Int; 2011 May; 79(10):1113-8. PubMed ID: 21270761
[TBL] [Abstract][Full Text] [Related]
38. Sodium Bicarbonate Treatment and Vascular Function in CKD: A Randomized, Double-Blind, Placebo-Controlled Trial.
Kendrick J; You Z; Andrews E; Farmer-Bailey H; Moreau K; Chonchol M; Steele C; Wang W; Nowak KL; Patel N
J Am Soc Nephrol; 2023 Aug; 34(8):1433-1444. PubMed ID: 37228030
[TBL] [Abstract][Full Text] [Related]
39. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
[TBL] [Abstract][Full Text] [Related]
40. Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes.
Żyłka A; Gala-Błądzińska A; Dumnicka P; Ceranowicz P; Kuźniewski M; Gil K; Olszanecki R; Kuśnierz-Cabala B
Dis Markers; 2016; 2016():8489543. PubMed ID: 28050059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
